EA201200211A1 - PHARMACEUTICAL COMPOSITION, ENJOYED WITH SPEATING, ANTI-CONGESTIVE, ANTI-INFLAMMATORY ACTION (OPTIONS) - Google Patents

PHARMACEUTICAL COMPOSITION, ENJOYED WITH SPEATING, ANTI-CONGESTIVE, ANTI-INFLAMMATORY ACTION (OPTIONS)

Info

Publication number
EA201200211A1
EA201200211A1 EA201200211A EA201200211A EA201200211A1 EA 201200211 A1 EA201200211 A1 EA 201200211A1 EA 201200211 A EA201200211 A EA 201200211A EA 201200211 A EA201200211 A EA 201200211A EA 201200211 A1 EA201200211 A1 EA 201200211A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
congestive
speating
enjoyed
options
Prior art date
Application number
EA201200211A
Other languages
Russian (ru)
Other versions
EA021295B1 (en
Inventor
Анастасия Геннадьевна ЧЕЛЯЕВА
Владимир Павлович ЛОБКО
Original Assignee
Анастасия Геннадьевна ЧЕЛЯЕВА
Владимир Павлович ЛОБКО
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Анастасия Геннадьевна ЧЕЛЯЕВА, Владимир Павлович ЛОБКО filed Critical Анастасия Геннадьевна ЧЕЛЯЕВА
Priority to EA201200211A priority Critical patent/EA021295B1/en
Priority to PCT/RU2013/000135 priority patent/WO2013129970A2/en
Publication of EA201200211A1 publication Critical patent/EA201200211A1/en
Publication of EA021295B1 publication Critical patent/EA021295B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к области фармацевтической промышленности и медицине, может быть использовано для создания и применения фармацевтических составов, обладающих сосудосуживающим, антиконгестивным, противовоспалительным действием, при острых ринитах, воспалительных процессах гайморовых полостей носа, носовых кровотечениях, конъюнктивитах. Задачей изобретения является создание фармацевтического состава на базе препарата нафазолин за счет введения в фармацевтический состав минеральных веществ, замещения в фармацевтическом составе изотопов углеродаС на изотопы углеродаС.The invention relates to the field of pharmaceutical industry and medicine, can be used to create and use pharmaceutical formulations with vasoconstrictive, anti-congestive, anti-inflammatory effects, for acute rhinitis, inflammatory processes of the maxillary sinus cavities, nosebleeds, conjunctivitis. The objective of the invention is to create a pharmaceutical composition based on the drug naphazoline by introducing into the pharmaceutical composition of mineral substances, substitution in the pharmaceutical composition of carbon isotopes with carbon isotopes.

EA201200211A 2012-02-29 2012-02-29 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments) EA021295B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201200211A EA021295B1 (en) 2012-02-29 2012-02-29 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
PCT/RU2013/000135 WO2013129970A2 (en) 2012-02-29 2013-02-20 Pharmaceutical composition having vasoconstricting, anticongestant and anti-inflammatory activity (embodiments)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201200211A EA021295B1 (en) 2012-02-29 2012-02-29 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)

Publications (2)

Publication Number Publication Date
EA201200211A1 true EA201200211A1 (en) 2013-07-30
EA021295B1 EA021295B1 (en) 2015-05-29

Family

ID=48916289

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200211A EA021295B1 (en) 2012-02-29 2012-02-29 Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)

Country Status (2)

Country Link
EA (1) EA021295B1 (en)
WO (1) WO2013129970A2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3470131B2 (en) * 1994-03-16 2003-11-25 大正製薬株式会社 Long-acting nasal drops
RU2156087C1 (en) * 1999-11-25 2000-09-20 Товарищество с ограниченной ответственностью Фирма "Электронная медицина" Biologically active addition
US20050080043A1 (en) * 2000-09-20 2005-04-14 Lee Shahinian Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
RU2251417C2 (en) * 2003-04-11 2005-05-10 Аникеев Сергей Владимирович Preparation for treating highmoritis named "antihighmoritis"
RU2281086C1 (en) * 2005-01-18 2006-08-10 Сергей Николаевич Анисимов Ophthalmic anti-histaminic drops
RU2412188C2 (en) * 2006-09-21 2011-02-20 Раквалиа Фарма Инк. Benzimidazole derivatives as selective acid pump inhibitors

Also Published As

Publication number Publication date
EA021295B1 (en) 2015-05-29
WO2013129970A2 (en) 2013-09-06
WO2013129970A3 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
EA201690246A1 (en) AUTOTOXIN INHIBITORS CONTAINING A NUCLEAR HETEROAROMATIC RING-BENZYL-AMIDE CYCLE
ECSP14013217A (en) 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDAS AND 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDAS AS BTK INHIBITORS.
EA201291034A1 (en) APTAMERS TO β-NGF AND THEIR APPLICATION IN THE TREATMENT OF B-NGF-MEDIATED DISEASES AND DISORDERS
EA201591166A1 (en) AUTOTAXIN INHIBITORS
EA201491281A1 (en) COMPOSITION IN THE FORM OF DRY POWDER CONTAINING CORTICOSTEROIDS AND β-ADRENERGIC MEDICINE FOR INTRODUCTION BY INHALATION
BR112015018838A2 (en) improved stability of new liquid compositions
EA201400771A1 (en) NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION
EA201201658A1 (en) DERIVATIVES OF PIPERIDINE AND THEIR APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
CL2016000510A1 (en) Compositions for orodispersible tablets containing corticosteroids for eosinophilic esophagitis
EA201690783A1 (en) SUBSTANCES, PHARMACEUTICAL COMPOSITION AND METHODS OF APPLICATION IN THE TREATMENT OF INFLAMMATORY DISEASES
MX2017003216A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients.
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
CL2016000677A1 (en) Compounds derived from ethynyl, positive allosteric modulators of the mglur4 receptor; pharmaceutical composition that includes them; and its use in diseases of the CNS, cancer and type 2 diabetes.
EA201690191A1 (en) PHARMACEUTICAL COMPOSITION FOR THE SLOWLY RELEASE OF LANREOTIDE
CY1123284T1 (en) COMPOSITION INCLUDING HYDROCORTISONE
EA201591259A1 (en) SOLID FORMS OF HINAZOLIN DERIVATIVE AND THEIR APPLICATION AS A BRAF INHIBITOR
EA201591450A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GLYCOSAMINO GLYCAN
AR093252A1 (en) ORAL PHARMACEUTICAL COMPOSITION USED AS ANTIPARASITARY AND ANTIDIARRICS AND PROCESSES TO PREPARE IT
MX359887B (en) Chewable composition for oral administration and process for preparing thereof.
PL3369429T3 (en) Pharmaceutical composition intended to be administered to nasal mucosa
MX2020006075A (en) Bendamustine pharmaceutical compositions.
EA201500313A1 (en) STABILIZED AMORPHOUS FORM OF AGOMELATIN, THE WAY OF ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS, ITS CONTAINING
EA201200211A1 (en) PHARMACEUTICAL COMPOSITION, ENJOYED WITH SPEATING, ANTI-CONGESTIVE, ANTI-INFLAMMATORY ACTION (OPTIONS)
IT1404270B1 (en) POSITIVE ALLGLASS MODULATORS OF MGLUR5 FOR USE AS MEDICATION IN THE THERAPEUTIC TREATMENT OF THE PHELAN-MCDERMID SYNDROME
EA201200301A1 (en) PHARMACEUTICAL COMPOSITION, ENJOYED WITH SPEATING, ANTI-CONGESTIVE, ANTI-INFLAMMATORY ACTION (OPTIONS)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU